In short
Cetuximab sarotalocan (ASP-1929) is an investigational light-activated therapy being studied in a Phase 3 trial for locoregional recurrent squamous cell carcinoma of the head and neck (HNSCC). The trial compares cetuximab sarotalocan combined with laser light and pembrolizumab against standard chemotherapy in 412 participants. Overall survival is the main measure of the trial.
Key points
- Cetuximab sarotalocan is an investigational light-activated cancer therapy also known as ASP-1929.
- It is being tested in a Phase 3 trial for locoregional recurrent head and neck squamous cell carcinoma.
- The trial includes 412 participants and is currently authorised.
- The main measure is overall survival — the time from randomisation to death from any cause.
- Treatment combines cetuximab sarotalocan with laser light and the immunotherapy pembrolizumab.
- A published case report describes temporary low blood calcium after treatment with cetuximab sarotalocan.
What is cetuximab sarotalocan?
Cetuximab sarotalocan is an investigational substance being studied for the treatment of locoregional recurrent squamous cell carcinoma of the head and neck (HNSCC). In the trial record it also appears under the development code ASP-1929. It is not described as an authorised medicine in the sources provided.
How does cetuximab sarotalocan work?
Cetuximab sarotalocan is a light-activated therapy. In the clinical trial, it is given together with illumination from a laser device called the PIT690 laser system. The substance is designed to be activated by light of a specific wavelength, which is intended to produce a treatment effect at the site of the tumour. The sources provided do not give further detail on the molecular target.
Which conditions is cetuximab sarotalocan studied for?
- Locoregional recurrence of squamous cell carcinoma of the head and neck (HNSCC) — a return of head and neck cancer in the same region as the original tumour, without distant metastases.
How is cetuximab sarotalocan given?
Cetuximab sarotalocan is given by intravenous infusion at a dose of 640 mg/m² in the trial. It is used together with illumination by the PIT690 laser system and with pembrolizumab (KEYTRUDA), an immunotherapy given intravenously at a dose of 400 mg. The comparison arm of the trial uses standard chemotherapy drugs, including 5-FU, paclitaxel, carboplatin, cisplatin and docetaxel.
What do the clinical trials show?
Which condition is being studied?
The single registered trial investigates cetuximab sarotalocan in locoregional recurrent squamous cell carcinoma of the head and neck with no distant metastases.
What phase is the trial in and what is its status?
The trial is a Phase 3 study, which means it is a large study comparing the new treatment against standard care. Its status is authorised, meaning it has received the necessary approvals to begin.
What is the trial measuring?
The primary outcome is overall survival (OS), defined as the time from randomisation to death from any cause.
Who can take part in the trial?
The trial is designed for people with locoregional recurrent squamous cell carcinoma of the head and neck without distant metastases. The planned number of participants is 412.
What side effects are known?
A published case report describes temporary hypocalcemia (low blood calcium) in a patient with hypoparathyroidism who received cetuximab sarotalocan. The low calcium occurred without low magnesium levels. This is a single case report, and the sources provided do not give a complete side effect profile for cetuximab sarotalocan.